Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ANI PHARMACEUTICALS INC Director's Dealing 2018

May 12, 2018

31676_dirs_2018-05-11_fc4fffc7-ea8d-46d4-a385-16a5f6479086.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ANI PHARMACEUTICALS INC (ANIP)
CIK: 0001023024
Period of Report: 2018-05-09

Reporting Person: MARSHBANKS TRACY (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2018-05-09 Common Stock S 20517 $62.05 Disposed 430084 Indirect
2018-05-10 Common Stock S 17685 $62.14 Disposed 412399 Indirect
2018-05-10 Common Stock S 24229 $62.03 Disposed 388170 Indirect

Footnotes

F1: This transaction was executed in multiple trades at prices ranging from $62.00 to $62.335. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F2: This transaction was executed in multiple trades at prices ranging from $62.00 to $62.5425. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3: This transaction was executed in multiple trades at prices ranging from $62.00 to $62.11. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F4: Held by FA Private Equity Fund IV, L.P., FA Private Equity Fund IV GmbH & Co. Beteiligungs KG, The Productivity Fund IV Liquidating Trust, and The Productivity Fund IV Advisors Fund Liquidating Trust, which the Reporting Person may be deemed to be a beneficial owner pursuant to rule 16a-1(a)(1).